Some IPOs fade into the background after their first week of trading. Alamar Biosciences (ALMR) is not one of them, though.
The proteomics company just went public on April 17, and it is already getting a big vote of confidence from Cathie Wood. ARK Invest's Genomic Revolution ETF (ARKG) added more than 500,000 shares right around the debut, which is the kind of move that naturally gets growth investors leaning in.
